Patients with relapsed or refractory diffuse large B-cell lymphoma who could not receive a stem cell transplant lived a median of 25.5 months on a bispecific antibody combination, compared with 12.5 months on the standard comparison regimen, according to three-year follow-up from a phase 3 trial.
The results, published in Blood Advances, come from the STARGLO trial, which randomized 274 patients 2 to 1 to glofitamab plus gemcitabine and oxaliplatin or to rituximab plus the same chemotherapy backbone. Median follow-up reached 35.1 months. Median progression-free survival was 14.4 months versus 3.3 months, and the complete response rate was 58.5% versus 25.3%.
